Back
3 MIN READ
A revolutionary cannabis based product recently entered the Colorado cannabis industry and many people have referred to it as the “Adderall of marijuana”.
The company behind this product is Cannabics Pharmaceuticals (CNBX), which is a biotech research company that develops its proprietary products out of its GMP certified laboratory in Israel and then licenses the use of these products in the United States. Cannabics does not manufacture, distribute, or dispense any controlled substances, including cannabis or cannabis-based products.
Shay Avraham is a co-founder of Cannabics Inc., and the founder of Seach, one of the oldest and largest medical cannabis farms in Israel. Seach is an official supplier of medical grade cannabis to the Israeli Ministry of Health and specifically licensed to grow and distribute medical cannabis to authorized patients.
A game changing product
In late June, Cannabics announced that its partner, Wana Products, launched WanaCaps xr, a series of extended release cannabis capsules that provide beneficial effects for up to multiple hours per dose.
Since 2010, Wana Products has been creating and selling marijuana infused products in Boulder, Colorado. Cannabics licensed its patented IP technology exclusively to Wanna due to their high quality control standards and business ethics. WanaCaps is offering three different formulations of the product:
- High CBD Capsules with a 10:1 CBD to THC ratio
- High THC Capsules with a 10:1 THC to CBD ratio
- Balanced Capsules with a 1:1 THC to CBD ratio
Mixed reactions to the product
Mountain High Products recently began offering the product through its dispensary and they have been very impressed with it.
The owner of Mountain High Products, John Whiteman said, “We feel like we are making an important step in giving patients another alternative in consuming cannabis.”
Dr. Kennon Heard at the University of Colorado Hospital is not so optimistic about the product and has urged caution with it.
Heard said, “The utility isn’t clear. We don’t have the medical knowledge to say that marijuana is useful to treat the vast majority of conditions that people are using it for.”
Outlook
Although the product sounds revolutionary, investors are not sold on it. Shares of CNBX are up less than 5% since announcing the release of the product and the company has only traded shares on three days.
During 2015, shares of CNBX are down 28% and we would be cautious at current levels. As the cannabis industry continues to develop and evolve, these types of products will see increased demand if researchers can validate the efficacy of the product.
Important Investor Disclosures:
Technical 420 LLC, and any of its directors, officers, employees, affiliates, or subsidiaries does not accept any form of compensation from companies in return for writing reports on them. Also Technical 420 LLC, and any of its directors, officers, employees, affiliates, or subsidiaries do not hold any stock positions in companies covered by MushroomstocksLLC. All information relied upon for the above report is publically available via various research resources, including third-party sources we consider reliable, but we do not guarantee that any of such information is accurate or complete.
All good -- no spamming here.
Comments